Arcturus Therapeutics Holdings Inc. Common Stock (ARCT)

About ARCT

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; an…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

106

Website

arcturusrx.com/

Fundamentals

1-day range

$14.49$15.9

Market cap

$170.54M

P/E (trailing)

—

P/E (forward)

-4.09

EPS (trailing)

$-3.31

Dividend yield

—

Beta

2.60

Avg. volume

755.4K

Dividend pay date

November 16, 2017

Forecasts

10 analyst ratings

Arcturus Therapeutics Holdings Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ARCT

  Arcturus Therapeutics Holdings Inc. Common Stock

  $15.19

  ▼ 6.06%
  Market cap $170.54MP/E —
  $5.5$24.17
• TNXP

  Tonix Pharmaceuticals Holding Corp. Common Stock

  $13.59

  ▲ 0.18%
  Market cap $170.01MP/E —
  $9.4$34.04
• EVO

  Evotec SE American Depositary Shares

  $1.91

  ▼ 2.80%
  Market cap $172.06MP/E —
  $3.18$7.3
• LFCR

  Lifecore Biomedical Inc. Common Stock

  $4.58

  ▲ 0.88%
  Market cap $164.67MP/E —
  $3.63$8.98
• OKUR

  OnKure Therapeutics Inc. Class A Common Stock

  $3.78

  ▼ 1.31%
  Market cap $162.39MP/E —
  $2.23$5.38
• NBP

  NovaBridge Biosciences American Depositary Shares

  $1.85

  ▼ 2.38%
  Market cap $185.76MP/E —
  $1.46$6.79
• AARD

  Aardvark Therapeutics Inc. Common Stock

  $5.71

  ▼ 13.75%
  Market cap $154.94MP/E —
  $3.35$17.94

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Broadcom, Palo Alto Networks Headline Earnings Amid A Tight Economic Calendar
  SeekingAlpha · 8/29/2026
• 12 Health Care Stocks Moving In Friday's Intraday Session
  Benzinga · 8/21/2026
• Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)
  benzinga · 8/20/2026
• Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)
  Benzinga · 8/20/2026
• Let's uncover which stocks are experiencing notable gaps during today's session.
  ChartMill · 8/19/2026
• Stay updated with the stocks that are on the move in today's pre-market session.
  ChartMill · 8/19/2026
• 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  Benzinga · 8/19/2026
• Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
  Yahoo · 8/12/2026
• Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/7/2026

• John Markels · June 5, 2026 · Grant

  15.0K
• Jing L. Marantz · June 5, 2026 · Grant

  15.0K
• Slaoui Moncef · June 5, 2026 · Grant

  15.0K
• Magda Marquet · June 5, 2026 · Grant

  15.0K
• Edward W. Holmes · June 5, 2026 · Grant

  15.0K
• James F. Barlow · June 5, 2026 · Grant

  15.0K
• Peter C. Farrell · June 5, 2026 · Grant

  15.0K
• Dennis Mulroy · May 1, 2026 · Grant

  100.0K

Institutional Ownership

March 31, 2026

Total shares held

23.34M

Total value held

$176.35M

Institutional holders

122